drugset / Trial / NCT05829317

Magnesium Prophylaxis for the Prevention of New-Onset Atrial Fibrillation in Critically Ill Patients

NCT05829317

RandomizedParallel-groupQuadruple-blindPrevention

Summary

A double-blind, multi-centre, randomized, placebo-controlled, feasibility pilot trial in the prevention of new onset atrial fibrillation of critically ill patients admitted to an ICU.

Timeline

Start
2023-08-20
Primary completion
2028-03-01
Completion
2028-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Magnesium Sulfate Other / unclassified 4 g Intravenous